While the research in combination therapy resulted in approval of PD-1/PD-L1 targeting drug combinations with cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockers, chemotherapy, drugs targeting vascular endothelial growth factor (VEGF) and drugs targeting intracellular kinases for over half-a-dozen types of cancer (Supplementary Table S1), additional studies are needed to further improve the response rates and to treat other types of cancer. The gene discussed is VEGFA; the disease is cancer.